Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2820)	2/7/2001 1:32:11 PM
From: scaram(o)uche	Read Replies (1) of 52153

re. Lehman/Mckinsey......... a question at Merrill Lynch, following the BMY presentation, asked for an opinion re. the report. Paraphrased response, by Peter Dolan....... It's easy to take shots. Yes, costs will increase, largely due to the "huge explosion in the number of targets available". Yes, new targets will lead to an increase in the attrition rate of drug candidates. However, advances at BMY have already been observed for oncopharmacogenetics. Linking pharmacogenomics to genomics will lead to increased output.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next